Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inupadenant plus carboplatin and pemetrexed in nonsquamous NSCLC after immunotherapy
2024-515393-27-00Phase 2Completed
- Sponsor
- iTeos Therapeutics
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Inupadenant + carboplatin + pemetrexed with Placebo to inupadenant + carboplatin + pemetrexed (2 arms). Primary endpoints: Safety and tolerability in Part 1 (dose-finding) and Progression-free survival (PFS). Started Sep 2024; status: completed.
02
Drugs
inupadenant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515393-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515393-27-00.